Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

executives in February 2007.

Total amortization with respect to intangible assets increased to $1.9 million in fiscal 2007 compared to $1.3 million in fiscal 2006.

On February 1, 2007 the Company recorded an impairment for the unamortized portion of the workforce intangible asset that was acquired in the Eximias acquisition on May 9, 2006. After the termination of the Phase III DEC trial in metastatic breast cancer, management re-evaluated the workforce intangible and determined it to be impaired because it is no longer a probable future economic benefit. This resulted in a write-down of $1.8 million, the net book value of the asset on the day of impairment.

Net losses for the fiscal year and fourth quarter ended June 30, 2007 were $31.7 million ($0.57 per share) and $4.7 million ($0.08 per share) respectively compared to $25.8 million ($0.59 per share) and $8.6 million ($0.16 per share) for the same periods last year.

As at June 30, 2007 the Company had cash and cash equivalents and short-term deposits totaling $75.6 million and payables and accrued liabilities totaling $3.3 million compared to $88.3 million and $3.7 million respectively at June 30, 2006.

As at June 30, 2007 the Company had 58,216,309 common shares outstanding, of which 2,380,953 common shares are held in escrow for contingent additional payment related to the acquisition of Delex Therapeutics Inc., 8,972,277 warrants, and 4,196,205 options.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treat
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
(Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... H.C. Birnboim , DNA Genotek, ... Oragene gives higher DNA yields than other oral, collection ... g. In comparison, buccal, swabs may yield as little as 1.9 ... Introduction , The number of studies ...
, , Daniel G. Flowers and Lloyd A. Culp, Ph.D., , , , back to top...
... Julie Chang, Bio-Rad Laboratories, Inc., 2000 Alfred Nobel ... Introduction , ... throughput and automating the sequencing process. This high-throughput , ... laboratories, driving such , achievements as the ...
Cached Biology Technology:DNA Yield with Oragene 2Comparison of Commercial Dye Terminator Removal Kits, Rev A 2Comparison of Commercial Dye Terminator Removal Kits, Rev A 3Comparison of Commercial Dye Terminator Removal Kits, Rev A 4Comparison of Commercial Dye Terminator Removal Kits, Rev A 5
(Date:7/13/2014)... New research raises the prospect of more effective treatments ... occurring in about half of all cancer patients, raising ... Cancer Institute. , Many strategies have been tried to ... patients can,t endure potentially life-saving treatments, but none have ... 13 advanced online edition of Nature , led ...
(Date:7/11/2014)... Society for Bone and Mineral Research awarded Michael F. ... (BUSM), with the 2014 Louis V. Avioli Award. Holick, ... is internationally known for revolutionizing the understanding of vitamin ... The award honors a member of the American Society ... to bone and mineral basic research. It is named ...
(Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... study, which was directed by Scripps Research Professor ... September 8 issue of The Journal of Biological ... than the one previously suggested-for the biosynthesis of ... endogenous cannabinoid ("endocannabinoid") anandamide. The high activity of ...
... Yujiang Song have discovered a better way to see where ... that produces novel hollow platinum nanostructures. , The research will ... German chemical journal Angewandte Chemie Int. Ed. In advance of ... the journal's web site. , Sandia is a National ...
... a common heavy metal are unable to obtain sufficient ... a new study presented at The American Physiological Society ... how cadmium, a heavy metal, reduces the oyster's tolerance ... during the summer when water temperatures rise. Half of ...
Cached Biology News:Study shows enzyme builds neurotransmitters via newly discovered pathway 2Sandia researchers discover way to see how a drug attaches to a cell 2Rising ocean temperatures, pollution have oysters in hot water 2Rising ocean temperatures, pollution have oysters in hot water 3Rising ocean temperatures, pollution have oysters in hot water 4
Adenylate kinase isoenzyme 6...
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Biology Products: